EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Vitro CRISPR-Cas12a-Based Detection of Cancer-Associated TP53 Hotspot Mutations Beyond the crRNA Seed Region

Kavish A V Kohabir iD, Lars O Nooi, Arjen Brink, Ruud H Brakenhoff, Erik A Sistermans, Rob M F Wolthuis

The CRISPR Journal · 2023

DOI: 10.1089/crispr.2022.0077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The CRISPR Journal, 2023. Verfasst von Kavish A V Kohabir und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: CRISPR-Associated Proteins, Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cost-effective and time-efficient detection of oncogenic mutations supports improved presymptomatic cancer diagnostics and post-treatment disease monitoring. Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas12a is an RNA-guided endonuclease that, upon protospacer adjacent motif (PAM)-dependent recognition of target DNA in cis , exhibits indiscriminate ssDNase activity in trans , which can be harnessed for diagnostics. TP53, one of the most frequently mutated tumor suppressor genes in cancer, displays recurring point mutations at so-called “hotspots.” In this study, we optimized Cas12a-based assay conditions for in vitro detection of six TP53 hotspot mutations at the codon for p.R273, located outside the Cas12a seed region, and evaluated the specificities of four commercial Cas12a variants. We found that nonengineered LbCas12a significantly outperformed the other tested nucleases specifically in distinguishing mutant p.R273 codons in synthetic DNA, mock cell-free DNA, and tissue biopsies, despite the suboptimal PAM-distal positioning of the corresponding mutations. Future clinical Cas12a-based applications may include point-of-care tumor analysis, cost-effective mutation screening, and improved monitoring of individual cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Associated ProteinsNeoplasmsHumansCRISPR-Cas SystemsRNA, Guide, CRISPR-Cas SystemsGene EditingBacterial ProteinsDNAMutationEndonucleasesTumor Suppressor Protein p53

Substanzen

RNA, Guide, CRISPR-Cas SystemsBacterial ProteinsCRISPR-Associated ProteinsDNAEndonucleasesTP53 protein, humanTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Department of Human Genetics, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Embryonic & Fetal Development, Amsterdam Reproduction & Development, Amsterdam, The Netherlands.
  • Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Department of Otolaryngology/Head and Neck Surgery, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

ORCID-Profile: Kavish A V Kohabir

Zitieren

APA

Kohabir, K. A. V., Nooi, L. O., Brink, A., Brakenhoff, R. H., Sistermans, E. A., & Wolthuis, R. M. F. (2023). In Vitro CRISPR-Cas12a-Based Detection of Cancer-Associated TP53 Hotspot Mutations Beyond the crRNA Seed Region. The CRISPR Journal. https://doi.org/10.1089/crispr.2022.0077

Vancouver

Kohabir KAV, Nooi LO, Brink A, Brakenhoff RH, Sistermans EA, Wolthuis RMF. In Vitro CRISPR-Cas12a-Based Detection of Cancer-Associated TP53 Hotspot Mutations Beyond the crRNA Seed Region. The CRISPR Journal. 2023. doi:10.1089/crispr.2022.0077

BibTeX
@article{Kohabir2023,
  author = {Kohabir, Kavish A V and Nooi, Lars O and Brink, Arjen and Brakenhoff, Ruud H and Sistermans, Erik A and Wolthuis, Rob M F},
  title = {In Vitro CRISPR-Cas12a-Based Detection of Cancer-Associated TP53 Hotspot Mutations Beyond the crRNA Seed Region},
  journal = {The CRISPR Journal},
  year = {2023},
  doi = {10.1089/crispr.2022.0077}
}
Kostenlos starten →